The VHH Company

The VHH Company

Welcome to


Excellence in Single Domain Biotherapeutics

Isogenica develops therapeutic VHH:
highly versatile small format antibodies which are used to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

Our VHH can be assembled to create bi-specific and multi-specific biotherapeutics for your target profile, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Synthetic libraries for faster discovery



At diversities of 1010  – 1013, Isogenica’s VHH libraries are the most diverse synthetic VHH libraries on the market. Typically, leads from Isogenica’s synthetic libraries have low nanomolar affinities, which are optimal for your drug development needs… read more about our libraries.

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline with three clinical partnered assets, including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.

Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents. Contact us today to see how we can work together with you to discover and develop your VHH solutions.


Isogenica Biopharmaceutical Partnerships

News & Events

Careers at Isogenica

A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.